Format

Send to

Choose Destination
J Biopharm Stat. 2006 May;16(3):275-83; discussion 285-91, 293-8, 311-2.

Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.

Author information

1
Novartis Pharmaceuticals, East Hanover, NJ 07936, USA. paul.gallo@novartis.com

Abstract

A PhRMA Working Group on adaptive clinical trial designs has been formed to investigate and facilitate opportunities for wider acceptance and usage of adaptive designs and related methodologies. A White Paper summarizing the findings of the group is in preparation; this article is an Executive Summary for that full White Paper, and summarizes the findings and recommendations of the group. Logistic, operational, procedural, and statistical challenges associated with adaptive designs are addressed. Three particular areas where it is felt that adaptive designs can be utilized beneficially are discussed: dose finding, seamless Phase II/III trials designs, and sample size reestimation.

PMID:
16724485
DOI:
10.1080/10543400600614742
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center